ReviewNature reviews. Gastroenterology & hepatology2016
Acute severe ulcerative colitis: from pathophysiology to clinical management.
Review in Nature reviews. Gastroenterology & hepatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 95 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
95 citing papers in PubMed, 2 syntheses or guidelines pooled it, 183 citations in OpenAlex.
- Second United Arab Emirates consensus guidance on the diagnosis and management of inflammatory bowel disease.World journal of gastroenterology · 2025Pooled it
- Predictors for colectomy in patients with acute severe ulcerative colitis: a systematic review and meta-analysis.BMJ open gastroenterology · 2024Pooled it
- Detecting microbial engraftment after FMT using placebo sequencing and culture enriched metagenomics to sort signals from noise.Nature communications · 2025Trial
- Adherence to guideline-recommended management in acute severe ulcerative colitis: a retrospective audit.Proceedings (Baylor University. Medical Center) · 2026Article
- Exploring the rationale for upfront corticosteroid-JAK inhibitor combination therapy in acute severe ulcerative colitis.EClinicalMedicine · 2026Review
- A survey on the practices and patterns in the management of acute severe ulcerative colitis in India.Intestinal research · 2026Article
- Partial responders to intravenous corticosteroids at day 3 benefit from continued therapy in acute severe ulcerative colitis.Scientific reports · 2026Article
- Alteration pattern of serum albumin levels in schizophrenia from first episode through remission to relapse: a longitudinal study.Translational psychiatry · 2026Article
- Enhanced Colon Regeneration in Ulcerative Colitis via Mesenchymal Stem Cell Medium and 17-β Estradiol.Immunity, inflammation and disease · 2026Article
- Managing Acute Severe Ulcerative Colitis in 2025 and Beyond.Current gastroenterology reports · 2026Review
- Microbial enzyme-responsive inulin nanoparticles for colon-targeted oral delivery of 5-ASA toward improved therapy of inflammatory bowel disease.Theranostics · 2026Article
- Early infliximab levels and clearance predict outcomes in acute severe ulcerative colitis.Translational gastroenterology and hepatology · 2026Article
- Article
- Ameliorative effects of combination therapy with metformin and crocin in experimental colitis in rats.Research in pharmaceutical sciences · 2025Article
- A ROS-responsive nanocarrier co-delivering cerium nanozymes and thalidomide for synergistic ulcerative colitis therapy.Materials today. Bio · 2025Article
- pH-responsive Oral liposomal delivery of hydrogen sulfide donor GYY4137 enables colon-targeted therapy for inflammatory bowel disease.Journal of nanobiotechnology · 2025Article
- Article
- Effects of Stress, Vagal Nerve Stimulation and Disease Activity on Circulating Cytokines, Quantified by an Ultrasensitive Technique, in Ulcerative Colitis: A Pilot Study.JGH open : an open access journal of gastroenterology and hepatology · 2025Article
- Predicting Outcomes in Hospitalized Patients With Acute Severe Ulcerative Colitis in a Prospective Multicenter Cohort.Inflammatory bowel diseases · 2025Observational
- Unveiling the Multifaceted Pharmacological Actions of Indole-3-Carbinol and Diindolylmethane: A Comprehensive Review.Plants (Basel, Switzerland) · 2025Review
35 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ulcerative colitis is a common chronic inflammatory disease of the colon and rectum, resulting from a dysregulated immune response towards intraluminal antigens in a genetically predisposed host. The disease has a varying extent and severity. Approximately 20% of patients with ulcerative colitis experience a severe flare during the course of their disease, requiring hospitalization. Acute severe ulcerative colitis (ASUC) is potentially a life-threatening condition that requires early recognition, hospitalization, correction of body fluids and electrolytes, and nutritional support if needed. Superimposed bacterial or viral infections need to be excluded and thromboprophylaxis should be started. Intravenous corticosteroids are the first-line treatment for this condition. Rescue treatment with ciclosporin or infliximab is indicated in patients who do not sufficiently respond to corticosteroids after 3-5 days, with close monitoring of the patients' symptoms, serum C-reactive protein and albumin levels. If medical therapy fails, timely colectomy should be performed to prevent critical complications. In this article, we review all relevant aspects of ASUC, from its pathophysiological background to modern management in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.